Extendicare (TSE:EXE – Free Report) had its target price boosted by TD Securities from C$10.50 to C$13.00 in a research note issued to investors on Monday,BayStreet.CA reports. The firm currently has a hold rating on the stock.
EXE has been the subject of a number of other research reports. BMO Capital Markets increased their target price on shares of Extendicare from C$11.00 to C$13.50 in a research report on Monday. Cormark raised shares of Extendicare to a “moderate buy” rating in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada lifted their target price on shares of Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a report on Thursday, November 28th. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, Extendicare has a consensus rating of “Hold” and an average price target of C$11.50.
Check Out Our Latest Stock Analysis on EXE
Extendicare Price Performance
Extendicare Announces Dividend
The business also recently declared a monthly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 17th will be issued a $0.04 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.48 annualized dividend and a dividend yield of 3.81%. Extendicare’s dividend payout ratio is currently 61.20%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- Options Trading – Understanding Strike Price
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Investing in Travel Stocks Benefits
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.